Online inquiry

IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10956MR)

This product GTTS-WQ10956MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A&IL17F gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002190.3; NM_052872.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 112744
UniProt ID Q16552; Q96PD4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10956MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8969MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ10137MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ3992MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ14577MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aCD1919
GTTS-WQ4769MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ3076MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ13391MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ7092MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW